Sterols and the sterol biosynthetic pathways are major targets for antifungal drugs. Amphotericin B and other polyenes selectively damage membranes that contain ergosterol, the major fungal sterol (5) . The imidazole antimycotics inhibit fungal growth by preventing 14-demethylation of lanosterol and effectively block synthesis of ergosterol (6, 11) , although some of these agents at higher concentrations destroy membranes directly, causing rapid killing (10) .
In our search for improved antifungal drugs or drug combinations, we examined the inhibition of fungal growth by pairs of drugs that inhibit sterol synthesis. Each pair contained ketoconazole. After preliminary experiments with 15 known sterol inhibitors, we chose 4 to examine in combination with ketoconazole: naftifine, an allylamine derivative that inhibits squalene epoxidase (7); 15-azasterol, which inhibits the reduction of the 14(15) double bond in the sterol nucleus (12) ; triarimol, an inhibitor of 14-demethylation (8); and mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (1) .
A variety of fungal pathogens, including yeast and filamentous fungi, were used. The organisms chosen were selected in part for their relative resistance to ketoconazole. Carefully standardized methods of determining MICs were adopted to ensure comparable data in the various experiments.
The aims of the study were to determine whether such combinations have clinical potential and to understand better the biosynthesis and the role of sterols in fungal membranes.
MATERIALS AND (Childrens' Hospital Medical Center, Boston, Mass.). The organisms were maintained by subculture on Sabouraud dextrose agar.
The sterol inhibitors used in this study were ketoconazole (Janssen R&D Inc., New Brunswick, N.J.), naftifine hydrochloride (Allergan Pharmaceuticals, Irvine, Calif.), mevinolin (Merck Sharp & Dohme, Rahway, N.J.), and triarimol and 15-azasterol (both from Eli Lilly & Co., Indianapolis, Ind.). A stock solution of mevinolin was prepared as described previously (1) . Stock solutions of the remaining chemicals were prepared in dimethyl sulfoxide.
All susceptibility tests were performed in the defined synthetic medium of Hoeprich and Finn (3), which is well buffered near the physiological range, pH 7.2 to 7.4. Yeast inocula were prepared from 18-to 24-h cultures in a liquid medium by dilution in sterile physiological saline. These were adjusted to a turbidity reading of 90% transmission at 540 nm. A further one-to fourfold dilution was made in saline, and this suspension was used for inoculation, giving a final inoculum of about 5 x 103 CFU/ml. For mycelial fungi, 24-to 48-h cultures in a liquid medium were vigorously vortexed with glass beads (2 mm in diameter), and the suspension was passed through a pad of sterile glass wool. The homogeneously turbid effluent was used for inoculation after adjustment of transmission and further dilution as described afbove. Table 1 shows the susceptibilities of the tested fungi to the sterol synthesis inhibitors used in this study..C. albicans VA was susceptible to ketoconazole. The other yeasts were from 16-to 64-fold more resistant to the drug. The filamentous fungi were also quite resistant to ketoconazole. As yet there is no standardized method for testing fungal susceptibility to The relevant data from the two drug checkerboard experiments are shown in Table 2 . We defined a significant result with a drug combination when a concentration of the second inhibitor below its MIC caused at least a fourfold decrease in the MIC of ketoconazole for that fungus.
With mevinolin, significant drug interactions as defined above were seen with C. albicans VA and the four filamentous fungi ( Would combinations of sterol synthesis inhibitors be too toxic to use in humans? Assuming no action other than the effect on sterol synthesis, it is unlikely that, at least with short-term treatment, humans would suffer toxicities from even profound inhibition of sterol synthesis. Unlike the fungi, humans can satisfy major cholesterol requirements from dietary sources and thus bypass a drug-induced block in cholesterol synthesis.
Based on work from our laboratory, we suggest that ketoconazole resistance depends on how well the organisms adjust to ergosterol depletion and to elevated levels of precursor sterols. With our present understanding there is no way to predict the effect an additional block of sterol synthesis at another site would have on a particular fungus and thus there will likely be no shortcut for testing the different combinations against ketoconazole-resistant organisms. The uniquely effective combinations observed, such as ketoconazole and naftifine versus A. niger or ketoconazole and azasterol versus C. albicans 7.22, the yeast with exceptionally high ketoconazole resistance, could not have been predicted.
